RxSight, Inc. (RXST)
| Market Cap | 227.68M -58.8% |
| Revenue (ttm) | 127.48M -14.0% |
| Net Income | -46.64M |
| EPS | -1.14 |
| Shares Out | 41.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 662,953 |
| Open | 5.56 |
| Previous Close | 5.62 |
| Day's Range | 5.45 - 5.90 |
| 52-Week Range | 4.48 - 13.22 |
| Beta | 1.15 |
| Analysts | Hold |
| Price Target | 8.57 (+55.82%) |
| Earnings Date | Aug 5, 2026 |
About RXST
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be... [Read more]
Financial Performance
In 2025, RxSight's revenue was $134.48 million, a decrease of -3.89% compared to the previous year's $139.93 million. Losses were -$38.94 million, 41.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for RXST stock is "Hold." The 12-month stock price target is $8.57, which is an increase of 55.82% from the latest price.
News
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST...
RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
Yesterday, the company said that the preliminary revenue view includes $5M-$7M in revenue recognized from the RxSight (RXST) Alcon Strategic Collaboration, with the specific amount expected to be repo...
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
Consensus $129.24M. The company said that the FY26 revenue view is inclusive of RxSight (RXST) sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110M...
RxSight price target lowered to $6.50 from $7.50 at Jefferies
Jefferies lowered the firm’s price target on RxSight (RXST) to $6.50 from $7.50 and keeps a Hold rating on the shares. Q2 preliminary results missed due to competitive trialing and…
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning ...
RxSight price target lowered to $6.50 from $8 at BofA
BofA lowered the firm’s price target on RxSight (RXST) to $6.50 from $8 and keeps an Underperform rating on the shares. The firm notes the company pre-announced preliminary Q2 sales…
RxSight Transcript: Investor update
A new collaboration with Alcon will drive development of adjustable PC IOLs, expanding innovation and market reach. Q2 revenue declined due to competitive trialing, prompting revised 2026 guidance and increased commercial investment. The product pipeline and clinical differentiation remain key growth drivers.
RxSight Press release: Investor update
RxSight issued a press release on July 7, 2026, disclosing material business information to investors.
Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs
Alcon (ALC) and RxSight (RXST) announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, or PCIOLs. Under the collaboration, the companies will be...
Alcon, RxSight announce collaboration to develop adjustable PCIOLs
The firm states: “Alcon (ALC) and RxSight (RXST) announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, or PCIOLs. Under the collaboration, the...
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic...
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone pr...
RxSight Slides: Investor presentation
RxSight has posted slides in relation to its latest quarterly earnings report, which was published on July 6, 2026.
Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
RxSight Transcript: Stifel 2026 Virtual Ophthalmology Forum
LAL volumes started 2026 in line with expectations, with premium IOL penetration rising despite lower cataract volumes. Competitive headwinds are expected to be less acute than in 2025, and commercial initiatives focus on same-store sales and clinician support. Long-term growth is driven by product differentiation and global expansion.
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is schedule...
RxSight Transcript: Bank of America Global Healthcare Conference 2026
Q1 results were ahead of expectations, with stable LAL sales and maintained revenue guidance. Growth is expected to improve sequentially, driven by deeper practice engagement and international expansion, while competitive headwinds are factored into guidance.
RxSight price target lowered to $11 from $13 at Needham
Needham lowered the firm’s price target on RxSight (RXST) to $11 from $13 and keeps a Buy rating on the shares after its Q1 results and affirmed revenue guide for…
RxSight reports Q1 adjusted EPS (19c), consensus (15c)
Reports Q1 revenue $30.89M, consensus $29.75M. “We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives,” said Ron Kurtz, President and Ch...
RxSight backs FY26 revenue view $120M-$135M, consensus $129.22M
Backs FY26 gross margin view 70%-72%.
RxSight Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined 18% year-over-year to $30.9 million, with LAL volumes stabilizing and gross margin improving to 76.1%. Guidance for 2026 was reiterated, with sequential growth expected and international expansion progressing, though near-term contributions remain modest.
RxSight Earnings release: Q1 2026
RxSight released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
RxSight Quarterly report: Q1 2026
RxSight has published its Q1 2026 quarterly earnings report on May 6, 2026.
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.
RxSight Slides: Corporate presentation
RxSight has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.